Top

Published in:

01-06-2009 | Original Paper

Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas

Authors: Jian Gu, Che Zhang, Rongguang Chen, Jun Pan, Yong Wang, Meng Ming, Weixing Gui, Dabin Wang

Published in: European Journal of Pediatrics | Issue 6/2009

Abstract

Extracellular matrix metalloproteinase inducer (EMMPRIN), a member of the immunoglobulin superfamily, is present on the surface of tumor cells where it stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPs). We have analyzed the clinicopathological characteristics of EMMPRIN and MMP2 expression in normal brain tissue and pediatric gliomas and evaluated their prognostic value in diagnosing the latter. Immunochemistry analysis revealed EMMPRIN and MMP2 expression in cryo-sections of pediatric gliomas (45 samples) and normal brain tissue (20 samples). Both EMMPRIN and MMP2 were expressed in normal brain and glioma tissues with different levels of malignancy. The intensively positive expression rates of EMMPRIN (22/27) and MMP2 (21/27) in anaplastic astrocytoma and glioblastoma tissues were significantly higher than those in normal brain and low-grade astrocytoma tissues (2/28 and ½8, respectively). Spearman analysis indicated that the expression level of EMMPRIN was significantly positively correlated with that of MMP2 (r = 0.86, p < 0.01). The positive expression of EMMPRIN and MMP2 was associated with higher grade gliomas. Patients with EMMPRIN+/MMP2+ expression had the lowest survival rate (p < 0.01). Based on these results, we conclude that EMMPRIN and MMP2 are expressed differently in normal brain and pediatric gliomas. The detection of their co-expression may facilitate the prediction of pediatric gliomas prognosis.

Brat DJ, Shehata BM, Castellano-Sanchez AA et al (2007) Congenital glioblastoma: a clinicopathologic and genetic analysis. Brain Pathol 17:276–281PubMedCrossRef

Marieb EA, Zoltan-Jones A (2004) Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res 64:1229–1232PubMedCrossRef

Gabison EE, Mourah S, Steinfels E (2005) Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio- stromal interactions and matrix metalloproteinase induction. Am J Pathol 166:209–219PubMed

Heppner KJ, Matrisian LM, Jensen RA et al (1996) Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 149:273–282PubMed

Sun J, Hemle ME (2001) Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 61:2276–2281PubMed

Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3:255–268PubMedCrossRef

Kossakowska AE, Huchcroft SA, Urbanski SJ et al (1996) Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin’s lymphomas in humans. Br J Cancer 73:1401–1408PubMed

London CA, Sekhon HS, Arora V et al (2003) A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 10:823–832PubMedCrossRef

Madigan MC, Kingsley EA, Cozzi PJ et al (2008) The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother 57:1367–1379PubMedCrossRef

10.

Lanyi M, Antonescu CR (2002) The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. Am J Pathol 160:1215–1221

11.

Mi Z, Oliver T, Guo H et al (2007) Thrombin-cleaved COOH (-) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res 67:4088–4097PubMedCrossRef

12.

Nabeshima K, Iwasaki H, Koga K et al (2006) Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56:359–367PubMedCrossRef

13.

Nakada M, Nakamura H, Ikeda E et al (1999) Expression and tissue localization of membrane-types 1, 2 and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 154:417–428PubMed

14.

Pulukuri SM, Patibandla S, Patel J et al (2007) Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene 26:5229–5237PubMedCrossRef

15.

Rainov NG, Söling A (2006) Clinical studies with targeted toxins in malignant glioma. Rev Recent Clin Trials 1:119–131PubMedCrossRef

16.

Ranuncolo SM, Armanasco E, Cresta C (2003) Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 106:745–751PubMedCrossRef

17.

Riethdorf S, Reimers N, Assmann V (2006) High incidence of EMMPRIN expression in human tumors. Int J Cancer 119:1800–1810PubMedCrossRef

18.

Sienel W, Hellers J, Morresi-Hauf A (2003) Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 103:647–651PubMedCrossRef

19.

Zucker S, Hymowitz M, Rollo EE (2001) Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 158:1921–1928PubMed

20.

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef

21.

Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99:157–166PubMedCrossRef

22.

Wykosky J, Gibo DM, Stanton C et al (2005) EphA2 as a novel molecular marker and target in glioblastoma multiform. Mol Cancer Res 3:541–551PubMedCrossRef

23.

Tang Y, Nakada MT (2005) Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating ascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65:3193–3199PubMed

24.

Ishibashi Y, Matsumoto T, Niwa M (2004) CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 101:1994–2000PubMedCrossRef

Title: Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas
Authors: Jian Gu
Che Zhang
Rongguang Chen
Jun Pan
Yong Wang
Meng Ming
Weixing Gui
Dabin Wang
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: European Journal of Pediatrics / Issue 6/2009
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-008-0828-5

At a glance: The STEP trials

Springer Medicine

Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2009

Reduced rate of adverse reactions to the BCG vaccine in children exposed to the vertical transmission of HIV infection and in HIV-infected children from an endemic setting in Brazil

Gallbladder wall thickening in a patient with acute poststrepotcoccal glomerulonephritis

First experiences with intraoperative Levosimendan in pediatric cardiac surgery

Many admissions to the emergency departments with recurrent syncope attacks and seizures in an adolescent boy

Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63 North American cases submitted to a patient registry

Late onset subgaleal hemorrhage infection with Streptococcus pneumoniae?